Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Next Previous
Trial Profile

A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM 101 (Primary) ; Capecitabine; Cetuximab; Cyclophosphamide; Fluorouracil; Folinic acid; Gemcitabine; Ipilimumab; Irinotecan; Nivolumab; Oxaliplatin; Paclitaxel; Pembrolizumab
  • Indications Advanced breast cancer; Cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms MODULATE
  • Sponsors Immodulon Therapeutics

Most Recent Events

  • 10 Jul 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
  • 01 Sep 2017 Status changed from active, no longer recruiting to discontinued.
  • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top